Literature DB >> 31774908

Expression of Nup93 is associated with the proliferation, migration and invasion capacity of cervical cancer cells.

Xiaolan Ouyang1, Xiaoming Hao1, Shuaibin Liu1, Jianguo Hu1, Lina Hu1.   

Abstract

Cervical cancer is a prevalent and devastating malignancy in females worldwide. Nucleoporin 93 (Nup93), a member of the nuclear pore complex, plays an important role in transport across the nuclear pore. Several nucleoporins have been linked to cancer. However, the oncogenic role and underlying mechanism of Nup93 in cervical cancer development have not been reported. In this study, the expression of Nup93 was analyzed by quantitative real-time polymerase chain reaction (qPCR), western blot analysis, and immunohistochemical staining in cervical cancer tissues and cell lines. We found that the expression of Nup93 was higher in cervical cancer samples, compared to normal cervical samples. The knockdown of Nup93 inhibited cell proliferation, migration, and invasion capacity of cervical cancer cells. At the same time, we also found that silencing of Nup93 could inhibit cellular migration and invasion by regulating cytoskeleton actin and Rho family proteins. Nup93 also participated in the IL-6/STAT3 signaling pathway. In addition, down-regulation of Nup93 prevented tumor formation in mice in vivo. Thus, Nup93 may be a carcinogenic gene and serve as a potential therapeutic target for cervical cancer.
© The Author(s) 2019. Published by Oxford University Press on behalf of the Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  IL-6; Nup93; Rho family; STAT3; cervical cancer

Mesh:

Substances:

Year:  2019        PMID: 31774908     DOI: 10.1093/abbs/gmz131

Source DB:  PubMed          Journal:  Acta Biochim Biophys Sin (Shanghai)        ISSN: 1672-9145            Impact factor:   3.848


  4 in total

1.  Development of an Interferon Gamma Response-Related Signature for Prediction of Survival in Clear Cell Renal Cell Carcinoma.

Authors:  Lixiao Liu; Xuedan Du; Jintao Fang; Jinduo Zhao; Yong Guo; Ye Zhao; Chengyang Zou; Xiaojian Yan; Wenfeng Li
Journal:  J Inflamm Res       Date:  2021-09-27

2.  Identification of UBE2I as a Novel Biomarker in ccRCC Based on a Large-Scale CRISPR-Cas9 Screening Database and Immunohistochemistry.

Authors:  Feng Li; Li Lai; Zhijie You; Hui Cheng; Guodong Guo; Chenchen Tang; Luyun Xu; Hongxia Liu; Wenting Zhong; Youyu Lin; Qingshui Wang; Yao Lin; Yongbao Wei
Journal:  Front Mol Biosci       Date:  2022-02-08

3.  Integrative multi-omics identifies high risk multiple myeloma subgroup associated with significant DNA loss and dysregulated DNA repair and cell cycle pathways.

Authors:  María Ortiz-Estévez; Fadi Towfic; Erin Flynt; Nicholas Stong; In Sock Jang; Kai Wang; Matthew W B Trotter; Anjan Thakurta
Journal:  BMC Med Genomics       Date:  2021-12-18       Impact factor: 3.063

4.  Silencing of ITGB6 inhibits the progression of cervical carcinoma via regulating JAK/STAT3 signaling pathway.

Authors:  Xiaoxia Zheng; Yanan Zhu; Xiaoping Wang; Yanmei Hou; Yingji Fang
Journal:  Ann Transl Med       Date:  2021-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.